AMICUS Aktie

 

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN), a pharmaceutical company, Friday announced that it has entered into a definitive agreement to acquire Amicus Therapeutics (FOLD), a biot......

BioMarin Pharmaceutical said on ⁠Friday it would acquire Amicus ‍Therapeutics ‍for about $4.8 ‍billion, expanding its presence in rare metabolic diseases....

BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash....

BioMarin Pharmaceutical Inc. agreed to buy Amicus Therapeutics Inc. for about $4.8 billion to expand its portfolio of treatments for rare diseases....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL AMICUS THERAPEUTICS INC. AM6 US03152W1099 BAW/UFN...

Instrument ID [7077] (AM6 - US03152W1099) suspended...

BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters Provides Opportunity to Expand Access to Galafold......

Empowering meaningful conversations and preserving independence for people living with dementia CHAPPAQUA, N.Y., Dec. 18, 2025 /PRNewswire/ -- Amicus Brain Innovations today announced the launch of Amicus INTERACT, a first-of-its-kind AI-powered application designed to provide real-time......

Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article....

Campbell, Bradley L. - Vorstand - Tag der Transaktion: 2025-12-15...

Clark, David Michael - Vorstand - Tag der Transaktion: 2025-12-15...

Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda....

The consensus price target hints at a 60.6% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions....

FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026....

INDIANAPOLIS, Dec. 4, 2025 /PRNewswire/ -- The National Police Association (NPA) today announced the filing of an amicus curiae brief with the U.S. Supreme Court in support of Los Angeles Police Department Officer Toni McBride, framing her case as a pivotal stand for America's embattled......

Campbell, Bradley L. - Vorstand - Tag der Transaktion: 2025-12-01...

DoJ Attempts To Save Face With "New" Pro-Gun Office & SCOTUS Filing Submitted by Gun Owners of America, Just recently, the Bondi DOJ filed an amicus brief in support of the Second Amendment in the Supreme Court case Wolford v. Lopez. But, gun owners are still rightfully furious with the Department of Justice and the Attorney General, Pam Bondi, for defending federal gun registration. So while GOA wholeheartedly supports the DOJ's filing in Wolford, that pro-gun brief stands in stark contrast to another anti-gun brief filed just days ago, in GOA's case against the National Firearms Act, Silencer Shop Foundation v. ATF. Today, @TheJusticeDept took decisive action to protect the Second Amendment by filing a brief in the Supreme Court challenging a Hawaii state law that effectively bans public carry. As our brief states, “Hawaii's law plainly violates the Second Amendment.” It's not just Hawaii… — Attorney General Pamela Bondi (@AGPamBondi) November 24, 2025 And this... In th...